Menu Search
Equities

Enhabit Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
X34:FRA

Enhabit Inc

Actions
  • Price (EUR)9.25
  • Today's Change-0.25 / -2.63%
  • Shares traded33.00
  • 1 Year change+13.50%
  • Beta1.2601
Data delayed at least 15 minutes, as of Feb 11 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Enhabit, Inc. is a provider of home health and hospice services in the United States. Its segments include Home Health and Hospice. The Home Health segment provides a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. It works closely with patients, families, caregivers, and physicians to deliver data-driven, evidence-based care plans focused on patient needs and goals. Its home health services are provided by nurses, physical, occupational and speech therapists, medical social workers, and home health aides. The Hospice segment provides hospice services to terminally ill patients and their families. Hospice care focuses on the quality of life for patients experiencing an advanced, life- limiting illness by treating the symptoms of the disease, rather than the disease itself. It operates about 115 hospice agencies and 255 home health agencies.

  • Revenue in USD (TTM)1.05bn
  • Net income in USD-11.90m
  • Incorporated2014
  • Employees10.70k
  • Location
    Enhabit Inc6688 N. Central Expressway, Suite 1300DALLAS 75206United StatesUSA
  • Phone+1 (469) 621-6419
  • Fax+1 (302) 655-5049
  • Websitehttps://www.ehab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.